Chelation therapy advertising rules: FDA and FTC

Chelation shows up in two very different places. In hospitals and toxicology clinics, prescription chelating drugs treat metal poisoning and iron overload. In some integrative, functional, naturopathic and anti-aging practices, chelation is offered as IV infusions or take-home products marketed for “heavy metal detox,” clogged arteries, autism and general wellness. The second setting is where advertising problems start.

This guide covers what FDA says about chelation products, what the NIH-funded heart trials found, how the FTC handled chelation advertising in the past, and how to write a service page that stays inside the evidence. For the wider category, see our guide to integrative medicine marketing claims. For drip services in general, see IV therapy clinic marketing. Colonics sold as a detox are covered in our guide to colon hydrotherapy marketing rules.

This is general information, not legal or medical advice. Sources cited were checked on November 1, 2026: FDA’s Questions and Answers on Unapproved Chelation Products (content current as of February 2, 2016); NCCIH’s Chelation for Coronary Heart Disease page (last updated August 2024); openFDA drug labeling data (last updated October 30, 2026); 21 USC 321, 352 and 355 and 15 USC 45, 52 and 55 in the Cornell LII text of the U.S. Code; the FTC’s December 1998 analysis of a proposed consent order and its 1999 notice reopening the comment period, both read in Internet Archive copies of June 17, 2026; the FTC Health Products Compliance Guidance (December 2022); and 16 CFR 255.2 and 233.1 in the eCFR version as of October 29, 2026. We did not review the full medical literature on chelation, ad platform policies, or state rules on who may order or give IV infusions.

The short version

Approved chelation drugs are prescription only. FDA says all FDA-approved chelation therapy products require a prescription because they can only be used safely under the supervision of a health care practitioner, and that it has never approved any chelation product for over-the-counter use for any health condition.
Approved uses are narrow. In FDA labeling data, prescription chelating agents are indicated for conditions such as lead poisoning and chronic iron overload from blood transfusions, not for detox, heart disease or autism.
FDA has named the claims it is worried about. Its Q&A lists autism spectrum disorders and heart conditions as the two common targets, plus Alzheimer’s disease, Parkinson’s disease and diabetes complications, and says there is no proof that “detoxification” with over-the-counter chelation products prevents or treats any condition.
The heart evidence does not support a claim. NCCIH says chelation for coronary heart disease has not been approved by FDA, and that the second NIH trial (TACT2, reported in 2024) did not reproduce the first trial’s results in people with diabetes.
The FTC has acted on chelation ads before. In 1998 it accepted a consent agreement with a physician association over claims that chelation treats blocked arteries and that studies proved it.

What chelation is and what FDA has approved

FDA describes chelation as the use of certain chemicals to remove heavy metals from the body, and says it has been used in medicine to treat metal poisoning, among other conditions. Its Q&A on unapproved chelation products (content current as of February 2, 2016) makes two points that matter for marketing: every FDA-approved chelation product needs a prescription, and FDA has never approved any chelation product for over-the-counter use for any health condition.

We looked at FDA’s drug labeling data through openFDA on November 1, 2026 (data last updated October 30, 2026). Labels classed as lead chelators or iron chelators carry indications such as treating lead poisoning in children above a set blood lead level, and treating chronic iron overload, including iron overload from blood transfusions. A database search is not a legal conclusion, but it shows the gap between what these drugs are approved for and what wellness ads often say.

If a page says a service uses an “FDA-approved” chelating agent, that statement can still mislead. FDA’s Q&A warns that unapproved products often highlight that they contain the same ingredient as an approved drug, and says this does not make it lawful to sell them without approval. An approved drug used for an unapproved purpose, such as detox or heart disease, is not “FDA-approved” for that purpose. Our guide to prescription treatment advertising covers how FDA and FTC rules divide up treatment ads.

Over-the-counter chelation and detox products

FDA’s Q&A says the products it warned about were marketed for home use to prevent or treat diseases, some as dietary supplements, in forms including nasal sprays, suppositories, liquid drops and clay baths. FDA’s position is that companies selling these products with unsubstantiated treatment claims violate the Federal Food, Drug, and Cosmetic Act and that, although some are sold as dietary supplements, they are in fact unapproved new drugs.

Under the Act, a product intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease is a drug (21 USC 321(g)(1)), and no one may introduce a new drug into interstate commerce unless an FDA approval of an application for it is in effect (21 USC 355(a)). A drug is misbranded if its labeling is false or misleading in any particular (21 USC 352(a)(1)).

For a practice, the practical point is simple: if you sell take-home chelation products, sprays, suppositories, clay baths or “detox” kits, the claims you make for them can turn them into unapproved drugs in FDA’s eyes. Our guide to selling supplements in a medical practice covers the supplement side.

Urine metal tests and “provoked” results

FDA’s Q&A also says some companies that make chelation products market screening tests that claim to detect heavy metals in urine “to falsely justify the need for the treatment,” that FDA has not cleared these tests, and that home test kits promoted to “diagnose” metal and other environmental toxicities were part of the marketing scheme in many of the companies it sent warning letters to.

If your funnel runs from a metal test to a chelation package, check two things. First, the test itself: who makes it, what it is cleared or authorized for, and what a result does and does not show. Second, the copy: “your test shows toxic metal levels, so you need 20 chelation sessions” is a claim that the test diagnoses a condition and that chelation treats it. Our guide to direct-to-consumer lab testing marketing covers test advertising.

Heart disease claims and the NIH trials

NCCIH’s page on chelation for coronary heart disease (last updated August 2024) answers the approval question directly: the use of this kind of chelation for coronary heart disease has not been approved by FDA. It describes two NIH-funded trials:

TACT (results reported in 2013) enrolled 1,708 people age 50 or older who had had a heart attack. NCCIH says chelation produced a modest reduction in cardiovascular events overall, but further analysis showed the beneficial effect occurred only in people with diabetes, and that the results were not, by themselves, sufficient to support routine use.
TACT2 (results reported in 2024) enrolled 1,000 people with diabetes and a prior heart attack to see whether that result could be replicated. Cardiovascular events occurred in 35.6 percent of the chelation group and 35.7 percent of the placebo group. Blood lead levels fell, but NCCIH says the findings do not support the use of chelation to reduce cardiovascular risk in people with diabetes and a history of heart attack.

NCCIH lists hypocalcemia (low blood calcium) and kidney damage as the most important serious side effects. FDA’s Q&A names dehydration, kidney failure and death as possible serious side effects, and says FDA is concerned that patients will delay proven, sometimes essential care when relying on unproven chelation for heart and blood vessel disease.

So a page that says chelation “clears arteries,” “reverses heart disease,” “is an alternative to bypass surgery” or “is proven by NIH research” is making claims the federal summaries do not support. Quoting the first trial without the second is the kind of selective reading the FTC treats as misleading. If you run a cardiology practice, our guide to cardiology practice marketing covers that specialty.

Autism and other disease claims

FDA’s Q&A names autism spectrum disorders as one of the two most common conditions unapproved chelation products claim to treat, and says these companies commonly target patients with serious and incurable diseases who may have limited treatment options. It also lists claims about Alzheimer’s disease, Parkinson’s disease and complications of diabetes.

Claims aimed at parents of autistic children deserve the most care of all. Do not name autism, ADHD or any developmental condition next to a chelation service, in ads, landing pages, social posts or phone scripts. If your practice offers evaluations, our guide to ADHD and autism evaluation marketing covers how to advertise those services.

What the FTC requires and what it has done

Section 5 of the FTC Act declares unfair or deceptive acts or practices in commerce unlawful (15 USC 45(a)), and section 12 makes it unlawful to disseminate a false advertisement to induce the purchase of drugs, devices or services (15 USC 52). Under 15 USC 55(a)(1), whether an ad is misleading includes what it fails to reveal about the consequences of using the product as the ad describes. The FTC Health Products Compliance Guidance says health claims need competent and reliable scientific evidence and that the agency looks at the net impression of an ad, including implied claims.

The FTC has applied this to chelation directly. Its December 1998 analysis of a proposed consent order describes a physician professional association that promoted chelation to the public through print materials and a website. The FTC alleged false and unsubstantiated claims about chelation’s effectiveness for atherosclerosis (blocked arteries) and about the existence of scientific proof. The proposed order barred the association from claiming chelation treats atherosclerosis, or making effectiveness claims for any disease of the circulatory system, without competent and reliable scientific evidence, and barred misrepresenting any test, study or research. It also required the association to send its members a letter saying any member who made unsubstantiated chelation claims could face enforcement.

The order had a 20-year sunset clause, so its terms are history. The standard it applied is not: effectiveness claims need competent and reliable scientific evidence, and an ad cannot misstate what studies show. The FTC’s analysis also said the action should not be read as regulating how doctors use or prescribe drugs in treating patients. The issue was the advertising.

Testimonials, reviews and packages

Chelation is often sold with patient stories and multi-session packages. Under 16 CFR 255.2(a), an advertiser needs substantiation for what consumer endorsements convey, just as if it had made the claims itself, so a review saying “my angina went away after chelation” carries a claim the clinic would need to support. Under 16 CFR 255.2(b), an endorsement about a central attribute is likely to be read as representative of what people generally get unless the ad clearly discloses the generally expected results. See our guide to patient testimonials and before-and-after photos.

For packages, state the price per infusion, what a package includes, how long it is valid, and refund and cancellation terms. A former-price comparison needs a price you actually offered in good faith for a reasonably substantial period of time (16 CFR 233.1(a)). Do not tie a package to a promised outcome, such as “30 infusions to clear your arteries.” See advertising cash prices.

What you can say

A practice that treats metal poisoning or iron overload under a physician’s care can say so, describe how patients are evaluated and referred, and explain what the visit involves. Lower-risk wording for any chelation page:

Who the service is for in clinical terms, how a clinician evaluates the patient first, and who orders and gives the infusion.
What a visit involves: length, monitoring, lab work, and what the patient will feel.
Known risks in plain words, and who should not receive it.
Price, package terms and cancellation policy.
If you mention research, the full picture: that NCCIH says the second NIH trial did not reproduce the first and does not support chelation for reducing cardiovascular risk in that group.

What to leave out: “detox” or “heavy metal cleanse” as a health promise, autism, Alzheimer’s, Parkinson’s or heart disease next to the service, “FDA-approved” for any unapproved use, “safe and natural,” success percentages, test-to-treatment funnels, and take-home chelation products.

An example (made up)

This illustration is invented to show how the rules fit together. An integrative clinic’s landing page says: “Chelation therapy removes toxic metals and clears your arteries without surgery. Proven by NIH research. FDA-approved ingredients. Helps children with autism. Order our home urine metals test, then start 20 infusions for $3,000, was $4,000.”

Fixes: “clears your arteries without surgery” and “helps children with autism” are disease claims that FDA has flagged and that need competent and reliable scientific evidence, so they come off. “Proven by NIH research” misstates the trials, since NCCIH says TACT2 does not support chelation for reducing cardiovascular risk, so it comes off. “FDA-approved ingredients” comes off because approval for metal poisoning or iron overload is not approval for this use. The home test funnel comes down. What is left describes physician evaluation, the infusion itself, risks, the price per session and the package terms. The $4,000 former price stays only if patients actually paid it for a reasonable period.

Checklist

No heart, autism, Alzheimer’s, Parkinson’s, diabetes or general “detox” claims for chelation (FDA Q&A; 15 USC 45, 52; FTC guidance).
No “FDA-approved” wording unless the drug is approved for the exact use described.
No take-home chelation sprays, suppositories, drops, clay baths or detox kits sold with health claims (21 USC 321(g)(1), 355(a)).
No test-to-treatment funnels built on unverified urine metal tests.
Research described accurately, including TACT2, not just the favorable part of TACT.
Serious risks and who should not receive it stated where the service is sold (15 USC 55(a)(1)).
Testimonials do not say what the clinic could not say (16 CFR 255.2).
Prices, package terms and former prices are real and clear (16 CFR 233.1).
Ads, social posts and phone scripts match the website.
Who may order and give IV infusions checked against your state’s rules.

How we help

We build service pages for integrative, wellness and cash-pay practices with claims checked against the sources above: website design, healthcare SEO for service searches, and lead generation campaigns that describe services without disease claims. We do not decide whether a treatment is safe or effective, we do not give legal opinions, and we are not a law firm. Related guides: ozone therapy marketing rules, infrared sauna marketing claims, naturopathic doctor marketing and functional medicine practice marketing.

Is chelation therapy FDA-approved?

Some chelating drugs are FDA-approved, all by prescription, for uses such as metal poisoning and iron overload. FDA says it has never approved any chelation product for over-the-counter use, and NCCIH says chelation for coronary heart disease has not been approved by FDA.

Can we advertise chelation as a heavy metal detox?

That is risky. FDA’s Q&A says there is no proof that detoxification using over-the-counter chelation products is effective to prevent or treat any condition or disease, and the FTC requires competent and reliable scientific evidence for health claims.

Did the NIH trials prove chelation works for heart disease?

No. NCCIH says the first trial, TACT, showed a modest reduction in cardiovascular events that was limited to people with diabetes, and that the second trial, TACT2, did not reproduce that result. NCCIH says TACT2’s findings do not support chelation to reduce cardiovascular risk in people with diabetes and a prior heart attack.

Can we mention autism on a chelation page?

We advise against it. FDA names autism spectrum disorders as one of the two most common conditions unapproved chelation products claim to treat and warns about serious side effects, including kidney failure and death.

Has the FTC acted on chelation advertising?

Yes. In 1998 the FTC accepted a consent agreement with a physician professional association over alleged false and unsubstantiated claims that chelation treats atherosclerosis and that studies proved it. The order required competent and reliable scientific evidence for such claims.

Sources

More in Cash-pay, aesthetic and wellness care

Chelation therapy marketing: approved uses vs detox, heart and autism claims